Our Experts in the News
-
Public Citizen petitions FDA for stricter warnings against Botox, similar drugs
December 12, 2023
Seeking Alpha
-
How the FDA approved an antipsychotic that failed to show a meaningful benefit but raised the risk of death
August 17, 2023
The BMJ
-
FDA advisors endorse Alzheimer’s treatment Leqembi paving way for full approval this summer
June 9, 2023
CNBC
-
Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease
June 9, 2023
STAT
-
Preterm Birth Drug Withdrawn After 12 Years
March 7, 2023
The New York Times
-
FDA decision on preterm birth drug’s withdrawal nears, putting spotlight on patients, agency
March 6, 2023
BioPharma Dive
-
Stella Immanuel Highest U.S. Prescriber of Ivermectin and HCQ
March 2, 2023
MedPage Today
-
Rx Repeat: Lecanemab
February 21, 2023
Full Measure
-
Investigation spotlights rise of for-profit ethics boards in research
February 16, 2023
The Washington Post
-
Novo Nordisk apologises for not disclosing sponsorship of anti-obesity training
February 12, 2023
Financial Times
-
Public Health Groups Doubt FDA’s ACNU Proposal Will Expand OTC Access, Benefit Public Health
January 17, 2023
HBW Insight
-
What a congressional investigation reveals about FDA's approval of Aduhelm
January 4, 2023
Advisory Board
-
House investigation faults FDA, Biogen for Alzheimer’s drug approval
December 29, 2022
The Washington Post
-
Gabapentin
December 4, 2022
Full Measure
-
Discipline for addicted physicians who relapse is often lenient, secretive
November 28, 2022
Investigate TV
-
Pulse Oximeters Need to Work Better for Dark-Skinned Patients, FDA Panel Says
November 2, 2022
MedPage Today
-
Private Practice: Confidential drug and alcohol programs for physicians keep patients in the dark
October 31, 2022
Hawaii News Now
-
Speedy FDA approvals in focus as agency weighs withdrawal of preterm birth drug
October 21, 2022
BioPharma Dive
-
FDA Wants Pregnancy Drug Off the Market
October 18, 2022
NBC Nightly News
-
Dueling announcements: As Biden touts cuts for Medicare Part B, study about a new Alzheimer's drug shows promise
September 28, 2022
Fierce Healthcare
Login
Subscribe